electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis
electroCore (Nasdaq: ECOR) has donated 20 gammaCore Sapphire D devices for a real-world evaluation of non-invasive vagus nerve stimulation (nVNS) among Israelis dealing with trauma. The study will be conducted by Dr. Yori Gidron from the University of Haifa and Dr. Robin Ely, Director of Integrative and Regenerative Medicine. Dr. Gidron, co-author of the PTSD Clinical Practice Guideline published by the Vagus Nerve Society, notes that PTSD is a debilitating psychiatric condition stemming from traumatic events, and nVNS presents a novel therapeutic solution.
electroCore (Nasdaq: ECOR) ha donato 20 dispositivi gammaCore Sapphire D per una valutazione nel mondo reale della stimolazione non invasiva del nervo vago (nVNS) tra israeliani che affrontano traumi. Lo studio sarà condotto dal Dr. Yori Gidron dell'Università di Haifa e dal Dr. Robin Ely, Direttore della Medicina Integrativa e Rigenerativa. Il Dr. Gidron, co-autore delle Linee Guida Cliniche per il PTSD pubblicate dalla Vagus Nerve Society, osserva che il PTSD è una condizione psichiatrica debilitante derivante da eventi traumatici, e la nVNS rappresenta una nuova soluzione terapeutica.
electroCore (Nasdaq: ECOR) ha donado 20 dispositivos gammaCore Sapphire D para una evaluación en el mundo real de la estimulación no invasiva del nervio vago (nVNS) entre israelíes que enfrentan traumas. El estudio será dirigido por el Dr. Yori Gidron de la Universidad de Haifa y el Dr. Robin Ely, Director de Medicina Integrativa y Regenerativa. El Dr. Gidron, coautor de la Guía de Práctica Clínica del PTSD publicada por la Vagus Nerve Society, señala que el PTSD es una condición psiquiátrica debilitante que proviene de eventos traumáticos, y la nVNS presenta una solución terapéutica novedosa.
electroCore (Nasdaq: ECOR)은 트라우마를 겪고 있는 이스라엘 사람들을 위한 비침습성 미주 신경 자극(nVNS)에 대한 실제 평가를 위해 20개의 gammaCore Sapphire D 장치를 기부했습니다. 이 연구는 하이파 대학교의 Yori Gidron 박사와 통합 및 재생 의학 소장인 Robin Ely 박사가 수행합니다. PTSD 임상 진료 지침의 공동 저자인 Gidron 박사는 PTSD가 외상 사건에서 파생되는 debilitating 정신 건강 상태이며, nVNS가 새로운 치료적 솔루션을 제공한다고 언급합니다.
electroCore (Nasdaq: ECOR) a fait don de 20 appareils gammaCore Sapphire D pour une évaluation dans le monde réel de la stimulation non invasive du nerf vague (nVNS) chez des Israéliens confrontés à des traumatismes. L'étude sera réalisée par le Dr Yori Gidron de l'Université de Haïfa et le Dr Robin Ely, directeur de la médecine intégrative et régénérative. Le Dr Gidron, co-auteur des lignes directrices de pratique clinique sur le PTSD publiées par la Vagus Nerve Society, note que le PTSD est une condition psychiatrique débilitante découlant d'événements traumatiques, et que la nVNS présente une nouvelle solution thérapeutique.
electroCore (Nasdaq: ECOR) hat 20 gammaCore Sapphire D Geräte gespendet, um eine realweltliche Bewertung der nicht-invasiven Vagusnervstimulation (nVNS) bei Israelis, die mit Trauma zu kämpfen haben, durchzuführen. Die Studie wird von Dr. Yori Gidron von der Universität Haifa und Dr. Robin Ely, dem Direktor für integrative und regenerative Medizin, geleitet. Dr. Gidron, Mitautor der klinischen Leitlinien zum PTSD, veröffentlicht von der Vagusnervgesellschaft, stellt fest, dass PTSD eine belastende psychiatrische Erkrankung ist, die aus traumatischen Ereignissen resultiert, und dass nVNS eine neuartige therapeutische Lösung darstellt.
- Potential expansion into PTSD treatment market through real-world evaluation
- Strategic collaboration with key opinion leaders in neuroscience and PTSD research
- None.
Insights
This real-world evaluation of gammaCore Sapphire for trauma treatment in Israel is not likely to generate meaningful near-term financial impact. The donation of 20 devices represents minimal cost impact and while the study could provide valuable clinical insights, the small sample size and observational nature limit its immediate commercial significance.
The focus on PTSD treatment aligns with electroCore's strategic expansion into mental health applications. The company's existing FDA clearances for cluster headache and migraine provide a foundation for potential expansion into psychiatric indications. However, significant regulatory hurdles and larger clinical trials would be needed before any meaningful revenue potential from PTSD applications.
ROCKAWAY, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has donated 20 gammaCore Sapphire D’s to be used by Dr. Robin Ely, Director of Integrative and Regenerative Medicine, a global practice focused on the development of integrated treatment regimens for neurocognitive and neurodegenerative disorders, and Dr. Yori Gidron, professor of health psychology at the Dept. of Nursing, Faculty of welfare and health sciences, University of Haifa and co-author of the PTSD Clinical Practice Guideline published by the Vagus Nerve Society. The real-world evaluation will be conducted by Dr. Gidron among Israelis dealing with trauma.
Peter Staats, MD, Chief Medical Officer of electroCore, commented, “PTSD remains a serious condition affecting the general population, and especially veterans and members of active-duty military, with limited therapeutic options. We are greatly appreciative of the opportunity to work with Dr. Gidron and Dr. Ely who helped coordinate this cross-border effort.”
Dr. Yori Gidron, study coordinator, commented, “PTSD is a debilitating psychiatric condition stemming from exposure to traumatic events which impact daily life and mental well-being. Non-invasive vagus nerve stimulation (nVNS) presents a novel therapeutic solution, and we appreciate electroCore’s donation of their gammaCore Sapphire devices to conduct this real-world evaluation.”
For more information on the PTSD Clinical Guideline, visit: VNS Society PTSD Clinical Guideline.
About the Vagus Nerve Society
The Vagus Nerve Society is a multidisciplinary global non-profit for all clinicians dedicated to the ongoing education and training of scientists and clinicians in the power of the vagus nerve and its application in a broad spectrum of health-related conditions.
To learn more, please visit https://www.vnsociety.org/
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the use of gammaCore Sapphire for symptoms of PTSD, electroCore's business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally in particular to accelerate training, and other statements that are not historical in nature, particularly those using terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize nVNS products, competition in the industry in which electroCore operates and general market conditions. The results of preclinical studies and clinical trials may not be predictive of results of future preclinical studies, clinical trials, or commercial success. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What is the purpose of electroCore's gammaCore Sapphire D donation in Israel?
How many gammaCore Sapphire devices did electroCore (ECOR) donate for the PTSD study?
Who will conduct the real-world evaluation of electroCore's (ECOR) devices in Israel?
